Abzena PLC | Cash Flow

Fiscal year is April-March. All values GBP Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,436.00
5,220.00
10,659.00
9,465.00
14,754.00
Depreciation, Depletion & Amortization
566.00
789.00
1,389.00
1,880.00
2,393.00
Other Funds
369.00
339.00
1,632.00
1,590.00
677.00
Funds from Operations
3,501.00
4,770.00
7,638.00
5,995.00
11,684.00
Changes in Working Capital
887.00
231.00
2,880.00
189.00
3,246.00
Net Operating Cash Flow
4,388.00
5,001.00
10,518.00
6,184.00
14,930.00
Capital Expenditures
146.00
1,082.00
2,047.00
3,320.00
6,107.00
Sale of Fixed Assets & Businesses
-
-
-
4.00
-
Net Investing Cash Flow
6,279.00
994.00
11,570.00
3,316.00
6,107.00
Issuance/Reduction of Debt, Net
-
-
-
118.00
226.00
Net Financing Cash Flow
10,670.00
19,037.00
20,013.00
89.00
23,687.00
Net Change in Cash
3.00
13,042.00
2,075.00
9,589.00
2,650.00
Free Cash Flow
4,534.00
6,083.00
12,551.00
9,496.00
21,037.00
Net Assets from Acquisitions
6,133.00
-
9,357.00
-
-
Other Sources
-
88.00
50.00
-
-
Change in Capital Stock
10,670.00
19,037.00
20,013.00
29.00
23,913.00
Other Uses
-
-
216.00
-
-

About Abzena

View Profile
Address
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT
United Kingdom
Employees -
Website http://abzena.com/
Updated 09/14/2018
Abzena Plc engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It operates through the following segments: Biology, Chemistry, and Biomanufacturing. Its services include: antibody discovery and candidate screening; immunology and immunogenicity assessment; antibody and protein engineering to reduce immunogenicity; and custom synthesis of cytotoxic payloads, reagents, and other small molecules.